Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/dc16-2385 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amyloidoma: A Case Report of Remote Insulin-Derived Amyloidosis in the Setting of Insulin-Dependent Diabetes.
Cureus
June 2024
Department of Graduate Medical Education and Pathology, Community Memorial Healthcare, Ventura, USA.
The incidence of insulin-induced amyloidosis distant from an injection site is unknown. Due to its rare nature, only a few case reports have been reported, with even fewer describing amyloidoma as distant from the insulin injection site. We present a case of a 52-year-old male with a left arm mass that was determined to be cutaneous amyloidosis and successfully treated with total excision of the mass.
View Article and Find Full Text PDFNR2F2 plays a major role in insulin-induced epithelial-mesenchymal transition in breast cancer cells.
BMC Cancer
July 2020
Department of Pathophysiology, Weifang Medical University, Weifang, 261053, China.
Background: The failure of treatment for breast cancer usually results from distant metastasis in which the epithelial-mesenchymal transition (EMT) plays a critical role. Hyperinsulinemia, the hallmark of Type 2 diabetes mellitus (T2DM), has been regarded as a key risk factor for the progression of breast cancer. Nuclear receptor subfamily 2, group F, member 2 (NR2F2) has been implicated in the development of breast cancer, however its contribution to insulin-induced EMT in breast cancer remains unclear.
View Article and Find Full Text PDFInsulin-Induced Distant Site Lipoatrophy.
Diabetes Care
June 2017
Division of Rheumatology, Endocrinology, and Nephrology, Hokkaido University Hospital, Sapporo, Japan.
Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
ACS Chem Biol
March 2011
Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, United States.
Inhibition of protein kinases has validated therapeutic utility for cancer, with at least seven kinase inhibitor drugs on the market. Protein kinase inhibition also has significant potential for a variety of other diseases, including diabetes, pain, cognition, and chronic inflammatory and immunologic diseases. However, as the vast majority of current approaches to kinase inhibition target the highly conserved ATP-binding site, the use of kinase inhibitors in treating nononcology diseases may require great selectivity for the target kinase.
View Article and Find Full Text PDFPathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.
Diabetes
November 2010
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
The objective of this research is to gain a greater understanding of the cause of fasting and postprandial hyperglycemia in people with type 2 diabetes. Endogenous glucose production is excessive before eating and fails to appropriately suppress after eating in people with type 2 diabetes. This is due in part to impaired insulin-induced suppression of endogenous glucose production, which is observed early in the evolution of type 2 diabetes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!